Case Reports
Vol. 17 No. 4 (2025)
https://doi.org/10.4081/dr.2025.10239

Psoriasiform rash possibly induced by oral propranolol in a 12-month-old girl with infantile hemangioma: a case report and literature review

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 5 March 2025
535
Views
318
Downloads
8
HTML
Psoriasiform, propranolol, infantile hemangioma

Authors

Sahar Alruhaimi
saharalruhaimi@gmail.com
https://orcid.org/0009-0008-8380-1263
King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Fatimah Alowirdi
Department of Dermatology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Waleed Al-Ajroush
Department of Pediatric Dermatology, King Abdullah Specialized Children’s Hospital, Riyadh, Saudi Arabia.

Infantile hemangiomas are the most common soft-tissue tumors in children, with propranolol, a non-cardioselective β-blocker, considered the first-line treatment for complicated cases. β-blockers have been reported to be the most common causative agents for drug-induced psoriasis in adults. In the pediatric population, only one previous case has been reported. We report the case of a 12-month-old girl who developed a psoriasiform rash after starting oral propranolol for infantile hemangiomas on the scalp. The patient had no personal or family history of psoriasis. The rash appeared one week post-initiation of propranolol, presenting as well-defined erythematous, scaly plaques over the body, including the scalp. Infectious causes were excluded, and the rash was diagnosed as a psoriasiform rash, possibly induced by oral propranolol. The patient was switched to atenolol, which resulted in improvement of the hemangioma and complete resolution of the skin lesions. This case highlights the rare but significant risk of psoriasiform eruptions associated with β-blocker therapy in infants, emphasizing the need for careful recognition and monitoring of this potential adverse effect in pediatric patients treated for infantile hemangiomas.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and Management of Infantile Hemangioma. Pediatrics 2015;136:e1060-104. DOI: https://doi.org/10.1542/peds.2015-2482
2. Tatu AL, Elisei AM, Chioncel V, et al. Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med 2019;18:955-9. DOI: https://doi.org/10.3892/etm.2019.7504
3. Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol 2018;35:170-81. DOI: https://doi.org/10.1111/pde.13382
4. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-65. DOI: https://doi.org/10.1001/archderm.143.12.1559
5. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633-6. DOI: https://doi.org/10.1111/j.1365-2133.2009.09593.x
6. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a populationbased study. Arch Dermatol 2005;141:1537-41. DOI: https://doi.org/10.1001/archderm.141.12.1537
7. Busch AL, Landau JM, Moody MN, Goldberg LH. Pediatric psoriasis. Skin Therapy Lett 2012;17:5-7.
8. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17:174-8. DOI: https://doi.org/10.1046/j.1525-1470.2000.01746.x
9. Dogra S, Kamat D. Drug-Induced Psoriasis. Indian J Rheumatol 2019;14:S37-43. DOI: https://doi.org/10.4103/0973-3698.272159
10. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol 2000;1:159-65. DOI: https://doi.org/10.2165/00128071-200001030-00003
11. Awad VM, Sakhamuru S, Kambampati S, et al. Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level. Cureus 2020;12:e8964. DOI: https://doi.org/10.7759/cureus.8964
12. Perman MJ, Lovell DJ, Denson LA, et al. Five cases of antitumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol 2012;29:454-9. DOI: https://doi.org/10.1111/j.1525-1470.2011.01521.x
13. Smith WA, Siegel D, Lyon VB, Holland KE. Psoriasiform eruption and oral ulcerations as adverse effects of topical 5% imiquimod treatment in children: a report of four cases. Pediatr Dermatol 2013;30:e157-60. DOI: https://doi.org/10.1111/j.1525-1470.2012.01780.x
14. Açikgöz G, Özmen I, Tunca M, et al. Psoriasis induced by growth hormone therapy in a patient with Turner’s syndrome. Int J Dermatol 2015;54:e132-5. DOI: https://doi.org/10.1111/ijd.12219
15. Fiorillo L, Wang C, Hemmati I. Rituximab induced psoriasis in an infant. Pediatr Dermatol 2014;31:e149-51. DOI: https://doi.org/10.1111/pde.12437
16. Baggio R, Le Treut C, Darrieux L, et al. Psoriasiform Diaper Rash Possibly Induced by Oral Propranolol in an 18-Month-Old Girl with Infantile Hemangioma. Case Rep Dermatol 2016;8:369-73. DOI: https://doi.org/10.1159/000455021
17. Wakefield PE, Berger TG, James WD. Atenolol-Induced Pustular Psoriasis. Arch Dermatol 1990;126:968-9. DOI: https://doi.org/10.1001/archderm.1990.01670310132028

How to Cite



1.
Alruhaimi S, Alowirdi F, Al-Ajroush W. Psoriasiform rash possibly induced by oral propranolol in a 12-month-old girl with infantile hemangioma: a case report and literature review. Dermatol Reports [Internet]. 2025 Mar. 5 [cited 2026 May 4];17(4). Available from: https://journals.pagepress.net/dr/article/view/10239
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.